Engineered Oncolytic Virus With Local Immune Co-Stimulation

The patent applies local quality by modifying the virus to express immune co-stimulatory molecules specifically at the tumor site and in tumor-draining lymph nodes. This localized expression enhances anti-tumor immune responses where needed while avoiding systemic activation that could cause off-target toxicity. The virus delivers molecules such as GITRL, 4-1-BBL, OX40L, ICOSL, or CD40L specifically to tumor microenvironments, creating different functional properties in different locations.

The patent uses composite materials by combining oncolytic virus with multiple immune co-stimulatory pathway molecules in a single therapeutic agent. The virus is engineered to express multiple molecules simultaneously (e.g., GITRL and CD40L, or 4-1-BBL and OX40L), creating a composite immunotherapeutic that activates multiple immune pathways converging on T cell activation. This composite approach enhances reliability by providing multiple mechanisms of immune activation.

The patent resolves this contradiction by applying local quality - the immune co-stimulatory molecules are expressed specifically in the tumor microenvironment and tumor-draining lymph nodes rather than being administered systemically. The virus delivers the therapeutic molecules locally, creating high concentration at the target site while maintaining low or absent levels in healthy tissues. This spatial differentiation achieves reliable immune activation at the tumor site while minimizing off-target toxicity to normal organs.

The oncolytic virus serves as an intermediary carrier that transports immune co-stimulatory molecules to the tumor site. Rather than administering the molecules systemically, the virus acts as a delivery vehicle that selectively infects tumor cells and releases the co-stimulatory molecules locally. This intermediary approach enables targeted immune activation without the systemic exposure that causes off-target toxicity.

The patent applies merging by combining multiple immune co-stimulatory molecules into a single oncolytic virus platform. Rather than administering multiple separate therapies, the virus is engineered to express multiple molecules (such as GITRL, 4-1-BBL, OX40L, ICOSL, or CD40L) simultaneously. These molecules converge on a common functional outcome - T cell activation - allowing their effects to be amplified while using a single delivery vehicle, thereby managing complexity.

The oncolytic virus serves multiple functions: it provides direct oncolytic activity by killing tumor cells, delivers immune co-stimulatory molecules to enhance immune responses, and acts as a vaccine platform by presenting tumor antigens. This multi-functionality allows a single therapeutic agent to address multiple aspects of cancer immunotherapy, improving reliability without requiring multiple separate interventions.